Sihuan Pharmaceutical : Voluntary Announcement - Update of Change of Senior Management

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. 四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock code: 0460) Voluntary Announcement Update of Change of Senior Management

The board of directors (the "Board") of Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical" together with its subsidiaries, the "Group") announces that:

1. APPOINTMENT OF DR. GUO FENG AS GROUP VICE PRESIDENT (RESEARCH AND DEVELOPMENT)

   Dr. GUO Feng ("Dr. GUO") has recently been appointed as Group Vice President (Research and Development ("R&D")). Dr. GUO will be primarily responsible for research and development division in the USA and clinical trial center.

   Dr. GUO, aged 47, brought to the Group nearly 20 years of experiences in innovative drug R&D and management especially in oncology drug R&D strategy making, clinical development, registration etc. In 2000, Dr. GUO obtained his PhD degree in Clinical Pharmacology from the University of Toronto in Canada. In 2001, Dr. GUO joined Pfizer Inc. ("Pfizer") as associate director at Pfizer Global R&D Headquarter based in Connecticut, US. In 2009, he was the Head of Clinical Pharmacology Asia of Pfizer in China. Since 2011, he was the Head of the Pfizer Wuhan R&D center which he played a key role in building. During his time in Pfizer, Dr. GUO participated in the global development (including in China) of multiple innovative drugs. In 2013, Dr. GUO joined Merck & Co., Inc. ("Merck") as Vice President of Global R&D and

   Head of Merck Biopharma (China) R&D Hub, a member of Merck Healthcare Global Clinical Development Executive Leadership team. During his service in Merck, Dr. GUO led his team in clinical development and registration of oncology drugs, including immune-oncology drugs, in China and Asia. In addition, Dr. GUO is an external scientific advisor of the Center for Drug Evaluation of China Food and Drug Administration ("CDE").

   The joining of Dr. GUO marked another key milestone in the Company's strategy in product research and development in both China and overseas. It is expected that his valuable experience in drug registration and clinical development would speed up the Company's R&D progress.

2. RETIREMENT OF MS. JIA ZHONGXIN, CHIEF OPERATING OFFICER

Ms. JIA Zhongxin ("Ms. JIA") has retired recently as Chief Operating Officer of the Group. As a senior management, Ms. JIA has devoted herself to the operation and development of the Group with an outstanding performance since joining the Group in 2008. She is highly respected by all of us in the Group.

I, on behalf of the Board, would like to express my gratitude to Ms. JIA for her outstanding contributions since her appointment as such and offer my best wishes to her.

Hong Kong, 31 July 2017

By order of the Board

Sihuan Pharmaceutical Holdings Group Ltd. Dr. Che Fengsheng

Chairman and Executive Director

As at the date of this announcement, the executive Directors of the Company are Dr. Che Fengsheng (Chairman), Dr. GUO Weicheng (Deputy Chairman and Chief Executive Officer) and Mr. Meng Xianhui; the non-executive Directors of the Company are Dr. Zhang Jionglong and Mr. Homer Sun; and the independent non-executive Directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Mr. Zhu Xun.